NasdaqGS:ALNYBiotechs
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Positive Long-Term HELIOS-B Results for AMVUTTRA
Alnylam Pharmaceuticals recently presented positive long-term data from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) at the European Society of Cardiology Congress 2025, showing durable reductions in all-cause mortality and cardiovascular events for adults with ATTR-CM across up to 48 months of treatment.
The study also highlighted sustained improvements in quality of life and days lost to death or hospitalization, with a consistent long-term safety profile supporting vutrisiran’s...